Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Therapy concepts in chronic hepatitis C]

B Meyer-Wyss1

  • 1Medizinische Abteilung, St Claraspital, Basel.

Schweizerische Medizinische Wochenschrift
|January 15, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.

Journal of viral hepatitis·2006
Same author

[Esophageal and intestinal stents].

Therapeutische Umschau. Revue therapeutique·2003
Same author

Helicobacter pylori and gastric erosions. Results of a prevalence study in asymptomatic volunteers.

Digestion·2000
Same author

Effects of a partially hydrolyzed guar gum on intestinal absorption of carbohydrate, protein and fat: a double-blind controlled study in volunteers.

Clinical nutrition (Edinburgh, Scotland)·1999
Same author

[CA19-9 has no value as a tumor marker in obstructive jaundice].

Schweizerische medizinische Wochenschrift·1999
Same author

Comparison between esophageal Wallstent and Ultraflex stents in the treatment of malignant stenoses of the esophagus and cardia.

Endoscopy·1997

Patients with normal liver enzymes and minimal liver damage should not undergo antiviral therapy. Those with significant liver inflammation or fibrosis benefit most from combination therapy, particularly within clinical trials.

Area of Science:

  • Hepatology
  • Virology
  • Internal Medicine

Context:

  • Chronic hepatitis C (HCV) management requires accurate risk stratification.
  • Liver biopsy remains crucial for assessing disease activity and fibrosis stage.
  • Alcohol consumption exacerbates HCV progression.

Purpose:

  • To define treatment strategies for chronic hepatitis C based on histologic findings.
  • To evaluate the efficacy of different antiviral regimens.
  • To identify optimal patient candidates for clinical trials.

Summary:

  • Patients with normal transaminases and no significant liver biopsy findings have a low risk of progression and poor response to current antiviral treatments.
  • Significant histologic activity or advanced fibrosis indicates a high risk for cirrhosis, especially with concurrent alcohol consumption.

Related Experiment Videos

  • Combination therapy (interferon plus ribavirin) significantly improves sustained virological remission rates (2-6 times higher than interferon alone), with potential further enhancement via high-dose, daily interferon (inductive dosing).

    • Impact:

    • Guides clinical decision-making for hepatitis C treatment initiation.
    • Highlights the importance of liver biopsy in treatment selection.
    • Emphasizes the superior efficacy of combination therapy for advanced disease.
    • Recommends enrollment in clinical trials for optimal management of significant chronic hepatitis C.